Astellas Pharma: Difference between revisions
No edit summary |
|||
| Line 8: | Line 8: | ||
| foundation = {{start date and age|2005|4|1|df=yes}} | | foundation = {{start date and age|2005|4|1|df=yes}} | ||
| predecessors = Yamanouchi Pharmaceutical<br />Fujisawa Pharmaceutical<br />(Merged in 2005) | | predecessors = Yamanouchi Pharmaceutical<br />Fujisawa Pharmaceutical<br />(Merged in 2005) | ||
| location = 2-5-1, Nihonbashi-Honcho, [[Chūō, Tokyo|Chūō-ku]], [[Tokyo]] 103-8411, Japan | | location = 2-5-1, Nihonbashi-Honcho, [[:en:Chūō, Tokyo|Chūō-ku]], [[:en:Tokyo|Tokyo]] 103-8411, {{Country|Japan}} | ||
| key_people = Naoki Okamura<br /><small>([[President (corporate title)|President]] and [[CEO]])</small><br />Kenji Yasukawa<br /><small>([[Chairman of the Board]])</small> | | key_people = Naoki Okamura<br /><small>([[President (corporate title)|President]] and [[:en:CEO|CEO]])</small><br />Kenji Yasukawa<br /><small>([[:en:Chairman of the Board|Chairman of the Board]])</small> | ||
| industry = [[Pharmaceutical company|Pharmaceutical]] | | industry = [[:en:Pharmaceutical company|Pharmaceutical]] | ||
| products = {{Unbulleted list|[[Prograf]]|[[Harnal]]|[[Vesicare]]|[[Micafungin| | | products = {{Unbulleted list|[[Prograf/ja|プログラフ]]|[[Harnal/ja|ハルナール]]|[[Vesicare/ja|ベシケア]]|[[Micafungin/ja|ファンガード/マイカミン]]|[[Protopic/ja|プロトピック]]|[[Xtandi/ja|イクスタンジ]]|その他医薬品}} | ||
| revenue = {{profit}} {{currency|11.06 billion}} ([[Fiscal year|FY]] 2013) | | revenue = {{profit}} {{currency|11.06 billion}} ([[:en:Fiscal year|FY]] 2013) | ||
| net_income = {{profit}} {{currency|1.28 billion}} ({{currency|1,139 billion|JPY}}) (FY 2013) | | net_income = {{profit}} {{currency|1.28 billion}} ({{currency|1,139 billion|JPY}}) (FY 2013) | ||
| assets = $14.86 billion (2016) | | assets = $14.86 billion (2016) | ||
| Line 23: | Line 23: | ||
[[File:AstellasPharmaCanada.jpg|thumb|Astellas Pharma office in Canada]] | [[File:AstellasPharmaCanada.jpg|thumb|Astellas Pharma office in Canada]] | ||
{{nihongo|'''Astellas Pharma Inc.'''|アステラス製薬株式会社|Asuterasu Seiyaku Kabushiki-gaisha}} | {{nihongo|'''Astellas Pharma Inc.'''|アステラス製薬株式会社|Asuterasu Seiyaku Kabushiki-gaisha}} は、日本の[[:en:Multinational corporation|多国籍]][[pharmaceutical company/ja|製薬企業]]であり、2005年4月1日に{{nihongo|'''Yamanouchi Pharmaceutical Co., Ltd.'''|山之内製薬株式会社|Yamanouchi Seiyaku Kabushiki-gaisha}}と{{nihongo|'''Fujisawa Pharmaceutical Co., Ltd.'''|藤沢薬品工業株式会社|Fujisawa Yakuhin Kōgyō Kabushiki-gaisha}}を合併して誕生した。2020年2月5日、同社は2020年4月1日付の経営陣交代を発表した。 | ||
Astellasは、[[Mitsubishi UFJ Financial Group|三菱UFJフィナンシャルグループ]] (MUFJ) [[:en:keiretsu|系列]]の企業である. | |||
==History== | ==History== | ||